WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Celltrion's Truxima wins FDA interchangeability designation

Celltrion said Wednesday that its blood cancer treatment Truxima received interchangeability designation from the US Food and Drug Administration, becoming the

Raccontata dakoreaherald.comkoreatimes.co.kr

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
koreaherald.comStai leggendo22 h fa

Celltrion's Truxima wins FDA interchangeability designation

Celltrion said Wednesday that its blood cancer treatment Truxima received interchangeability designation from the US Food and Drug Administration, becoming the

originale
koreatimes.co.kr21 h fa

Celltrion secures FDA's 1st interchangeable status for Rituximab biosimilar - The Korea Times

A key cancer treatment developed by Celltrion has become the first rituximab biosimilar to receive interchangeability status from the United States...

Leggi questa versione → originale

Timeline cronologica

  1. mercoledì 1 luglio 2026·koreaherald.com

    Celltrion's Truxima wins FDA interchangeability designation

    Celltrion said Wednesday that its blood cancer treatment Truxima received interchangeability designation from the US Food and Drug Administration, becoming the

  2. mercoledì 1 luglio 2026·koreatimes.co.kr

    Celltrion secures FDA's 1st interchangeable status for Rituximab biosimilar - The Korea Times

    A key cancer treatment developed by Celltrion has become the first rituximab biosimilar to receive interchangeability status from the United States...